Venatorx Pharmaceuticals Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-leading Antibiotics Developer
July 27, 2017
Venatorx Pharmaceuticals Receives $9.4 Million From CARB-X To Develop A New Class Of Antibiotic To Combat Multi-drug Resistant Bacteria
The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents beta-lactam antibiotic resistance, but with the same safe and effective mechanism of action of beta-lactams.
July 25, 2017
Venatorx Pharmaceuticals Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-leading Antibiotics Developer
Proceeds will be used to advance the Venatorx Pharmaceuticals' portfolio, including lead product candidate VNRX-5133 for multi-drug resistant (MDR) gram-negative infections.
Archive: 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 |
You are using a browser that is not supported. Please consider changing your browser